Bearish flow noted in GSK (GSK) Pharma with 2,330 puts trading, or 1.1x expected. Most active are 2/14 weekly 36 puts and 2/28 weekly 36 puts, with total volume in those strikes near 1,600 contracts.

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

Vivian Wan / Bloomberg via Getty Images GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK's Beat-and-Raise ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. When investing, your capital is at risk. The value of your ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

(Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion ...

GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to £2.21B, with Arexvy sales ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s shares opened today at p1,435.00. Leverage the ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure for the infectious disease. On a media call Wednesday morning ...